Joining C2MP will provide Tieös with access to world-class mentors in the biotech space and allow the company to accelerate its drug development programs for the US healthcare market.
The initial collaborative project between Tieös and the LDI will focus on in vitro validation of Tieös’ lead compounds and will be conducted at the Pollak Lab, led by Researchers from McGill University.
Tieös is pleased to be joining the Emergence Bioscience Business Incubator. This partnership will provide Tieös with access to advisory and consulting services as it moves ahead in executing on its drug development strategy and plans for continued growth.
Tieös is pleased to announce the appointment of world-renowned research oncologist Dr. Michael Pollak to the company's Advisory Board.
Tieös has been selected as a finalist in the 2017 BioInnovation Challenge being held in Halifax, Nova Scotia. The program allows up and coming life sciences companies to compete in the challenge and kick start their success.